Healthcare Provisions of the Inflation Reduction Act
By Vita on August 16, 2022
Rx Pricing Negotiation
The bill empowers the Centers for Medicare Services (CMS) to negotiate drug prices under Medicare. CMS will be able to negotiate prices for ten high-cost drugs starting in 2026 (15 in 2027 and 20 in 2029 and beyond). While considered a modest start, this approach will allow time to see whether price negotiation negatively affects drug development and stifles new drugs coming to the market (the major criticisms from the pharmaceutical industry).$35 Cap on Insulin
The out-of-pocket cost of insulin will be capped at $35 for individuals under Medicare. The bill initially included a cap on the out-of-pocket cost of insulin for all Americans. However, expanding the cap to a greater commercial marketplace was stripped out of the bill by the Senate parliamentarian. In order to pass the bill by a simple majority, all provisions must relate directly to the federal budget, and it was determined the expanded cap did meet that standard, so it could not be part of a reconciliation-eligible (filibuster-proof) bill.$2,000 Hard Cap on Medicare Part D
Redesigning Medicare Part D benefits to cap out-of-pocket costs has received wide support. The cap in the bill contains a $2,000 "hard" cap on out-of-pocket costs for prescription drugs under Medicare Part D. This provision becomes effective in 2025, and the cap will be indexed in future years.Extension of ACA Premium Subsidies
Supplemental ACA premium subsidies for low-income individuals, which were implemented as part of the 2021 American Rescue Plan Act, were set to expire at the end of 2022. This would have increased out-of-pocket premium payments across the board for virtually all 13 million subsidized enrollees. The bill extended the enhanced premium subsidies for three years.Impact on Employer Plans: Higher Costs
The healthcare provisions of the Inflation Reduction Act prompt a key question for employers: How will employer plan costs be impacted?In short, the cost savings for Medicare and for individuals covered under Medicare will likely be borne by employer health plans (and individual health plans). As Medicare negotiates "savings" in drug costs for Medicare recipients and for the federal government, we can expect a cost shift where that savings will be shifted to employer plans, self-funded plans, and individual plans. Drug manufacturers will receive lower revenue on the Medicare side (due to the CMS negotiation power), so we can expect that higher prices will be charged to commercial plans to compensate for the lost revenue.
- April 2025 (1)
- March 2025 (4)
- February 2025 (1)
- January 2025 (2)
- December 2024 (4)
- November 2024 (1)
- October 2024 (5)
- September 2024 (1)
- May 2024 (3)
- March 2024 (4)
- February 2024 (1)
- January 2024 (4)
- December 2023 (1)
- November 2023 (7)
- October 2023 (3)
- September 2023 (5)
- June 2023 (2)
- May 2023 (5)
- April 2023 (5)
- February 2023 (7)
- January 2023 (2)
- November 2022 (1)
- October 2022 (2)
- September 2022 (2)
- August 2022 (4)
- June 2022 (1)
- May 2022 (2)
- January 2022 (1)
- December 2021 (1)
- November 2021 (2)
- August 2021 (1)
- May 2021 (2)
- April 2021 (1)
- March 2021 (3)
- December 2020 (1)
- November 2020 (1)
- October 2020 (1)
- September 2020 (1)
- June 2020 (1)
- March 2020 (3)
Subscribe by email
Share this
You May Also Like
These Related Stories
Medicare Part D Creditability Determination: What Employers Need to Know for 2025

Medicare Part D Creditability Determination: What Employers Need to Know for 2025
October 15, 2024
13
min read
2024 Medicare Part D Creditable Coverage Criteria

2024 Medicare Part D Creditable Coverage Criteria
May 23, 2023
3
min read
The Latest on Rx Data Collection (RxDC)

The Latest on Rx Data Collection (RxDC)
March 5, 2024
4
min read